A Multicenter Randomized Double-Blind Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease who Failed Prior Biologic Treatment @ Long Island Clinical Research Associates
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Crohn's Disease
-
Age: Between 18 years - 80 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
- Male or female aged >=18 to <= 80 years at the Baseline Visit. Confirmed diagnosis of Crohn’s Disease (CD) for at least 3 months prior to Baseline.
- Demonstrated intolerance or inadequate response to one or more biologic therapies.
You may not be eligible for this study if the following are true:
-
- Subject with a current diagnosis of Ulcerative Colitis (UC)
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.